Key Points
- Rocket Pharmaceuticals General Counsel Martin Wilson sold 3,493 shares at an average price of $3.38, totaling $11,806.34. The transaction covered tax withholding obligations tied to vested equity awards and reduced his ownership by 0.52%.
- Rocket Pharmaceuticals reported quarterly EPS of $1.08, beating analysts’ consensus estimate of $0.86. The stock opened at $3.40, with a market capitalization of approximately $373 million.
- Analyst sentiment remains mixed, with the stock holding an average rating of “Hold” and a consensus price target of $8.57; institutional investors own 98.39% of the company.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) General Counsel Martin Wilson sold 3,493 shares of the business's stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $3.38, for a total value of $11,806.34. Following the completion of the transaction, the general counsel owned 674,484 shares of the company's stock, valued at $2,279,755.92. This trade represents a 0.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Martin Wilson also recently made the following trade(s):
- On Tuesday, May 19th, Martin Wilson sold 662 shares of Rocket Pharmaceuticals stock. The shares were sold at an average price of $3.01, for a total value of $1,992.62.
Rocket Pharmaceuticals Price Performance
Rocket Pharmaceuticals stock opened at $3.40 on Tuesday. Rocket Pharmaceuticals, Inc. has a 1 year low of $2.53 and a 1 year high of $5.45. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.24 and a current ratio of 9.24. The firm has a 50 day moving average price of $3.40 and a 200 day moving average price of $3.60. The company has a market cap of $373.25 million, a price-to-earnings ratio of -20.00 and a beta of 0.47.
Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The biotechnology company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.86 by $0.22. During the same period last year, the business earned ($0.62) EPS. Sell-side analysts predict that Rocket Pharmaceuticals, Inc. will post -1.4 earnings per share for the current year.
Hedge Funds Weigh In On Rocket Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC lifted its holdings in shares of Rocket Pharmaceuticals by 148.4% in the first quarter. AQR Capital Management LLC now owns 163,622 shares of the biotechnology company's stock valued at $1,091,000 after buying an additional 97,758 shares during the period. Millennium Management LLC grew its holdings in Rocket Pharmaceuticals by 121.8% during the first quarter. Millennium Management LLC now owns 747,147 shares of the biotechnology company's stock worth $4,983,000 after acquiring an additional 410,238 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Rocket Pharmaceuticals during the first quarter worth about $189,000. Goldman Sachs Group Inc. raised its position in Rocket Pharmaceuticals by 24.0% in the first quarter. Goldman Sachs Group Inc. now owns 995,690 shares of the biotechnology company's stock worth $6,641,000 after acquiring an additional 192,905 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Rocket Pharmaceuticals by 1.8% in the second quarter. Geode Capital Management LLC now owns 2,030,891 shares of the biotechnology company's stock worth $4,976,000 after acquiring an additional 36,847 shares in the last quarter. Institutional investors own 98.39% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts have commented on RCKT shares. Wall Street Zen upgraded shares of Rocket Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Monday. Weiss Ratings lowered shares of Rocket Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, August 11th. Wedbush reduced their price target on shares of Rocket Pharmaceuticals from $16.00 to $15.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 11th. Finally, Chardan Capital reiterated a "buy" rating and issued a $11.00 price target on shares of Rocket Pharmaceuticals in a research note on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $8.57.
View Our Latest Stock Report on Rocket Pharmaceuticals
About Rocket Pharmaceuticals
(
Get Free Report)
Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.
The company's pipeline comprises multiple product candidates in various stages of development.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
